| Literature DB >> 29329996 |
Merrylee McGuffin1, Naila Devji2, Lyann Kehoe2, Anne Carty2, Steve Russell2, Lisa Di Prospero3, Carlo DeAngelis4, Alex Kiss5, Danny Vesprini6, Andrew Loblaw6, Laura D'Alimonte7.
Abstract
INTRODUCTION: Radiation therapy is a standard treatment option for prostate cancer. With growing use of escalated doses and tighter margins, procedures to limit rectal size variation are needed to reduce prostate motion, increase treatment accuracy, and minimize rectal toxicity. This prospective study was done to determine whether the introduction of an antiflatulent medication would decrease rectal distention at computed tomography (CT) simulation and throughout a course of radiation therapy. METHODS AND MATERIALS: Patients undergoing a radical course of radiation therapy to the prostate/prostate bed were eligible to participate. Participants were randomly assigned to the intervention arm (antiflatulent medication) or the control arm (no medication). For each participant, the number of CT simulation rescans was recorded. Rectal diameters were measured on CT simulation and treatment cone beam CT scans. Acute rectal toxicities were assessed at baseline and weekly using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0. A χ2 analysis was used to compare the number of participants requiring a rescan in each study arm. Change in rectal diameter over time was assessed using repeated measures analysis of variance.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29329996 DOI: 10.1016/j.prro.2017.10.012
Source DB: PubMed Journal: Pract Radiat Oncol ISSN: 1879-8500